Sankara Nethralaya pays tribute to Dr. Namperumalsamy
'Dr. Nam', as he was fondly known, was chairman-emeritus of Madurai-based Aravind Eye Hospital. He died on Thursday (July 25, 2025) at the age of 85.
Recalling memories, T. Surendran, chairman, Sankara Nethralaya, spoke of his first meetings with Dr. Nam at workshops at Aravind Eye Hospital and of his simple, unassuming personality. 'His association with Sankara Nethralaya dates back to its inception,' he said and added that they hoped to ensure his legacy endured.
Gullapalli N. Rao, founder, L.V. Prasad Eye Institute in Hyderabad, said that he had known Dr. Nam for nearly 60 years, and his wife G. Nachiar, for even longer. Recalling him as a simple, humble, and informal person, Dr. Rao said that he had learnt a lot from Dr. Nam's experiences. 'His contribution [to Aravind Eye Hospital] was the creation of strong sub-specialities and training programmes. He also created the research centre,' Dr. Rao said, adding that Dr. Nam had fought with the management to keep research funded and had constantly advocated for research.
The two doctors then signed a condolence card, and all delegates at the conference who wished to sign it were asked to do so, with the card to be sent to Aravind Eye Hospital subsequently, organisers of the event said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
27 minutes ago
- Hans India
Mangaluru NGO inducted into WHO's Global Civil Society Commission
Mangaluru: Ina significant international recognition, Mangaluru-based Anti Pollution Drive Foundation (APDF) has been inducted into the Civil Society Commission of the World Health Organisation (WHO), joining a global network of organisations shaping the future of public health and environmental well-being. The Commission, created by WHO to strengthen collaboration with civil society actors, focuses on key areas including primary healthcare, gender rights, health equity, and community-based health interventions. APDF's membership was confirmed through a letter jointly signed by Commission co-chairs Ravi Ram and Lisa Hilmi. The Foundation was selected from a global pool of nearly 680 applicants after a multi-phase review and due diligence process by WHO. APD Foundation has earned a reputation for pioneering projects in air quality management, inclusive sanitation, and occupational health in urban settings. Its initiatives—such as Smart Swaccha Mangaluru (in partnership with UN-Habitat), Shuddha Gaali, and Waste Wise Cities—have combined grassroots activism with data-driven policy advocacy. Commenting on the milestone, APDF founder Abdullah A. Rehman said, 'This inclusion validates our approach of combining community action with evidence-based solutions. It also brings attention to how smaller cities like Mangaluru can be models of public health innovation.' The WHO Commission held its first annual general meeting in March 2024 and laid out a two-year action plan while forming three working groups to guide engagement with global civil society. APDF's induction is seen as a move towards diversifying voices in international forums and ensuring representation from cities outside of traditional urban centres.
Economic Times
3 hours ago
- Economic Times
Hims & Hers Q2 revenue drop shakes stock—Hims crashes 11% after first-ever revenue decline, is the weight-loss drug hype finally fading?
Hims & Hers Health (NYSE: HIMS) saw its stock plunge over 11% after the company reported its Q2 2025 earnings, marking its first-ever sequential revenue decline. While revenue jumped 73% year-over-year to $544.8 million, it still fell short of Wall Street's expectations of $552 million, and notably dropped from $586 million in Q1. The miss has rattled investor confidence, especially as GLP-1 weight-loss drug sales, a key growth driver, showed signs of slowing amid regulatory pressure and legal setbacks. Synopsis Hims & Hers stock dropped a sharp 11% after the company missed Q2 2025 revenue estimates, raising concerns about its booming weight-loss drug business. While year-over-year sales jumped 73%, revenue fell sequentially for the first time, causing investor worry. The company brought in $544.8 million, short of forecasts, with much of it tied to its GLP-1 obesity drug offerings. Hims & Hers Health (NYSE: HIMS), the fast-growing telehealth company known for its personalized care plans and buzzy entry into the weight-loss market, saw its stock drop by over 11% after reporting second-quarter 2025 earnings. While revenue jumped 73% year-over-year, the company missed Wall Street expectations and posted its first-ever sequential revenue decline, raising questions about the future of its GLP-1 obesity drug business. ADVERTISEMENT Despite its rapid annual growth, Hims & Hers posted Q2 revenue of $544.8 million, missing the analyst estimate of $552 million. The real concern? Revenue dropped from $586 million in Q1, marking the first quarter-over-quarter decline since the company went public. The stock currently trades at $63.35, regaining some ground after hitting an intraday low of $54.82. Despite opening at $64.00, it remains volatile, with an intraday high of $65.54. ALSO READ: Bullish IPO debut: Peter Thiel-backed crypto giant targets $4.2B valuation—is the new crypto wave knocking on Wall Street's door? The market reacted sharply to the company's revenue miss—$544.8 million vs. $552 million expected—even though earnings per share beat expectations and subscriber numbers remained strong. Most of the company's revenue stemmed from its GLP-1-based obesity and diabetes treatments, a booming but increasingly scrutinized business segment. ALSO READ: Palantir stock soars after $1B Q2 earnings crush forecasts as AI demand fuels 110% YTD surge—now S&P 500's top performer ADVERTISEMENT With regulatory pressures, lawsuits from Novo Nordisk, and tighter FDA rules on compounded semaglutide, Hims faces headwinds in its fastest-growing segment. However, with a market cap of over $6.5 billion, a P/E ratio of 39.93, and forward-looking confidence via its Zava acquisition, the company is still betting big on growth in both the U.S. and Europe. Current Price : $63.35 : $63.35 Day Range : $54.82 – $65.54 : $54.82 – $65.54 Open : $64.00 : $64.00 Market Cap: $6.56 Billion P/E Ratio : 39.93 : 39.93 Volume: 35.5M Investors were caught off guard, as the slowdown came amid soaring demand for weight-loss drugs like semaglutide, a compound similar to the active ingredient in Wegovy and Ozempic. ADVERTISEMENT On the profit front, Hims reported an adjusted EPS of $0.19, beating the Street's expectation of $0.15. However, the revenue miss overshadowed this earnings win. Investors appeared more concerned about the underlying business momentum, particularly in the obesity treatment space, which has been a major driver of Hims' recent growth. ADVERTISEMENT Hims' biggest growth story in recent quarters has been its expansion into GLP-1 weight-loss treatments, which brought in around $190 million in Q2 alone. However, a few red flags have emerged: Regulatory uncertainty : With the FDA rolling back flexibility on compounded versions of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. : With the FDA rolling back flexibility on of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. Legal challenges : The company recently ended its supply relationship with Novo Nordisk , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. : The company recently ended its supply relationship with , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. Competitive pressure: Big players like Eli Lilly and Novo Nordisk are dominating the branded drug market, making it harder for telehealth companies offering generics to compete on pricing and trust. Despite the Q2 shortfall, Hims & Hers stuck to its full-year outlook. The company reaffirmed its 2025 guidance of $2.3 billion to $2.4 billion in revenue and $295 million to $335 million in adjusted EBITDA. ADVERTISEMENT A big reason? The Zava acquisition, a European telehealth platform, which is expected to contribute around $50 million in new revenue this year. This suggests Hims is betting heavily on international growth to offset some of its domestic uncertainty. One bright spot in the report was Hims' growing subscriber base. The company now serves over 2.4 million active subscribers, with nearly 70% enrolled in personalized treatment plans that span weight loss, hair care, sexual health, and mental wellness. CEO Andrew Dudum emphasized that the company is leaning deeper into its long-term strategy of personalized digital healthcare, aiming to build loyalty and customer lifetime value across multiple product categories. If you're following Hims & Hers stock or investing in telehealth companies focused on the obesity drug boom, here are four key things to monitor: Future of compounded GLP-1s: Regulatory and legal outcomes could limit Hims' ability to sell compounded semaglutide at scale. Profitability trends: Will margins hold up as more competition floods the market and Hims scales its personalized offerings? Subscriber growth and retention: Continued engagement in non-weight loss categories will be key to long-term stability. Zava integration: The success or failure of this acquisition could make or break Hims' international ambitions. Hims & Hers Health has come a long way as a digital-first wellness brand with a bold strategy around weight-loss drugs and personalized healthcare. But the 11% stock drop shows investor sentiment is shifting, especially as its flagship obesity business faces regulatory hurdles and supply uncertainty. For now, the company's strong year-over-year growth and firm 2025 guidance offer some reassurance. But with rising competition, tighter FDA rules, and legal pressure, Hims will need to prove that its success isn't just tied to a single product wave—but a durable, trusted digital care ecosystem. What caused Hims & Hers stock to fall 11% after Q2 earnings? The company missed revenue estimates and saw its first-ever sequential drop in sales. Is the Hims weight-loss drug business facing trouble in 2025? Yes, due to FDA scrutiny and legal issues around compounded semaglutide. (You can now subscribe to our Economic Times WhatsApp channel) (Catch all the US News, UK News, Canada News, International Breaking News Events, and Latest News Updates on The Economic Times.) Download The Economic Times News App to get Daily International News Updates. NEXT STORY
Hindustan Times
3 hours ago
- Hindustan Times
Restaurants use unsafe colouring agent: Karnataka minister on quality food
Karnataka Health Minister Dinesh Gundu Rao on Monday appealed to people not to be "fooled" by attractive and colourful dishes, but to insist on safe and quality food. He cited the recent testing of six samples belonging to the Empire Group of Restaurants, which turned out to be unsafe due to the use of banned synthetic colouring.(PTI) He cited the recent testing of six samples belonging to the Empire Group of Restaurants, which turned out to be unsafe due to the use of banned synthetic colouring. "Despite repeated warnings, the restaurant group continued to use the unsafe colouring agent. Only after legal notices were sent did the colour go from red to yellow," the health minister told reporters during his weekly media briefing. There was no response from the Empire Group of Restaurants. According to the minister, better quality food and drugs can become the norm only if people insist on quality goods. "Yes, the government needs to do its part and tackle this legally, but people too should cultivate quality conscious as culture," he said. The minister also said the health department held a video conference on July 30 with cooking oil manufacturers to insist that the trans-fat level should not exceed 2 per cent. "We told them that if it exceeds 2 per cent, strong action will be taken against them," he added. Dinesh Gundu Rao said the oil manufacturers were also urged to sell used cooking oil (UCO) to manufacturers like Pyrene Industries, which converts UCO into biodiesel. According to 2024-25 data, 28,73,124 litres of UCO were used to manufacture biodiesel and soap, he said. "We want this figure to increase substantially so that UCO does not go back into the market for cooking purposes," he added. Rao said the Karnataka government has merged the enforcement division of Ayurveda, Siddha and Unani (ASU) medicines under the AYUSH Department, as well as the existing AYUSH drug testing laboratory in Bengaluru, with Drug Control Division of the Food Safety and Drug Administration Department for better functioning of the Health Department. According to him, the government's proposed app to control drug safety is expected to be functional by the end of this month. "With this app, we can immediately withdraw defective drugs, as we can track at distributor level. So, we can put an immediate stop to further sale of that drug," said the minister. He said, once the app is in force, they will expand its scope. "Next will be to take it to the pharmacy level. We want to onboard every pharmacy on the app," he added. At present, the recall procedure takes two days, he said, citing the recent recall of nearly 40 lakh drugs in two days. "This too, we had made a breakthrough with the help of a software. Earlier, it used to take nearly 30 days to recall batches of failed drugs from the market," he added. The minister also said work is progressing at expected pace in bringing the private ambulances and mobile medical units under the ambit of Karnataka Private Medical Establishments (KPME) Act. "We will be coming out with an amendment soon," he added.
